Catheter Precision (NYSEAMERICAN:VTAK) Issues Quarterly Earnings Results, Beats Estimates By $5.14 EPS

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($8.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($13.30) by $5.14, FiscalAI reports. The business had revenue of $1.84 million for the quarter, compared to the consensus estimate of $2.80 million. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.

Catheter Precision Price Performance

Shares of Catheter Precision stock opened at $0.15 on Tuesday. The stock has a market cap of $2.17 million, a price-to-earnings ratio of -0.02 and a beta of -0.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. The stock has a 50 day moving average price of $0.69 and a 200-day moving average price of $7.25. Catheter Precision has a one year low of $0.13 and a one year high of $3.20.

Catheter Precision Company Profile

(Get Free Report)

Catheter Precision is a medical technology company focused on products for electrophysiology, the specialty concerned with diagnosing and treating abnormal heart rhythms. Its products are designed to support clinicians during procedures involving cardiac arrhythmias. The company’s VIVO system uses patient-specific imaging and electrical data to create a three-dimensional view of the heart and help clinicians locate the source of ventricular arrhythmias before ablation procedures. Catheter Precision also offers LockeT, a device intended to assist with closure of femoral venous access sites after procedures.

Read More

Earnings History for Catheter Precision (NYSEAMERICAN:VTAK)

Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.